Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. ... agreement with MSN Laboratories Pvt. Ltd. ( Hyderabad, ... to commercialize several new ANDAs.  Under the terms of ... products exclusively to Breckenridge for the U.S. market, and ... label.  Breckenridge and MSN have agreed to develop an ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 /PRNewswire/ ...  Sorrento), an oncology company developing new treatments for ... privately-held immuno-oncology company developing proprietary Neukoplast ® ... announced today that the companies have entered into ... CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the treatment ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... the healthcare sector have benefited the Massage Services ... the discretionary characteristics of industry products, the anticipated 1.0% ... five-year period has provided consumers with the means to ... that have received a massage in a given year ...
(Date:12/20/2014)... The print component of Healthy Aging is ... approximately 160,000 copies and an estimated readership of 420,000. ... social media strategy and across a network of top ... version of the campaign, click here . , ... ladies of CTV’s The Social. Lainey Lui, Melissa ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Atore, Inc, ... company just launched first birthday focused portal on December ... BIRTHDAY MESSAGE” launched in both US and Japan. , ... MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE ... birthday around the world. , Features, Choose from thousands ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... that the scents of peppermint or cinnamon could make the ... for long stretches of time makes the drivers of the ... drivers who participated in the study under the conditions of ... control. The odors were added to the air inside the ...
... having fractures, are often routinely prescribed vitamin D and supplemental// ... light the fact that this may not be true. Calcium ... in the elderly people. ,The study had looked into ... people were mobile before they had a low trauma fracture. ...
... risk factor for multiple sclerosis. New study shows that ... suffering from multiple sclerosis. ,In a research done ... had been able to associate habitual smoking with rapid ... study comprising of 201 cases of multiple sclerosis and ...
... that it is possible to generate insulin from brain stem ... was given to patient suffering from type 1 diabetes mellitus, ... where there is availability of insulin, even there remains a ... such is inability of the patient to synthesize insulin in ...
... journal cancer Research, tobacco smoke have been linked with the ... 2 is a cellular protein that had been related to ... been related to rise in production of two proteins that ... lead to the production of the chemical Cox 2. ...
... that intake of calcium supplements over the years can ... of colon cancer.// ,Calcium supplements can reduce ... in colon. Calcium has chemo protective properties that can ... study was in a trial, which observed 930 patients ...
Cached Medicine News:
... Platelet aggregometers allows to choose the ... Single, dual and four sample units ... or digital computer outputs. In addition ... measure platelet aggregation in platelet-rich-plasma (PRP), ...
... a four channel Platelet Aggregation Profiler with ... assay (Ristocetin cofactor), platelet aggregation and leukocyte ... for the evaluation and confirmation of Heparin ... tests to be run simultaneously and independently. ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Medicine Products: